Amer Zeidan, MBBS

Amer Zeidan, MBBS, MHS is a Professor of Medicine at Yale School of Medicine. He serves as the Chief of the Division of Hematologic Malignancies, Director of Hematology Early Therapeutics Research, and Assistant Director of the Clinical Trial Office for Hematology at Yale Comprehensive Cancer Center (YCC). He is also the leader of Leukemia and Myeloid malignancies Clinical Research Team. Dr. Zeidan obtained his medical degree with honors from University of Jordan, followed by residency in Rochester General hospital, Rochester, NY. He then completed a Hematology/Oncology fellowship and a clinical research fellowship in myelodysplastic syndromes (MDS) at Johns Hopkins University where he also earned a Master of Health Science (MHS) degree in Clinical Investigation. He joined Yale Faculty in 2014 where he has become an internationally recognized expert in myeloid malignancies. Dr Zeidan has been conducting research on the development of novel therapies for myelodysplastic syndromes and acute myeloid leukemia (AML) with a special focus on targeted and immunotherapy-based approaches.

Dr. Zeidan has and continues to serve as study chair and principal investigator of multiple investigator-initiated, cooperative group and industry sponsored clinical trials for myeloid malignancies. He previously served as the vice chair of the YCC Data and Safety Monitoring Committee (DSMC) and as chair of Protocol Review Committee (PRC). He has served on multiple steering committees and independent data and safety monitoring committees for randomized and registrational clinical trials. Dr. Zeidan is also a member of the MyeloMATCH Precision medicine initiative of the National Cancer Institute (NCI) for MDS and AML and is very active within the Cancer Therapy Evaluation Program (CTEP) and Early Therapy Clinical Trial Network (ETCTN) focusing on early phase clinical trials of novel therapies for myeloid malignancies.

Dr Zeidan has contributed to the approval of multiple drugs for myeloid malignancies including oral decitabine/cedazuridine (Lancet Haematology), luspatercept (NEJM and Lancet), and imetelstat (Lancet). Dr Zeidan has been active in organizing the scientific community on important initiatives including publishing a guidance on management of MDS/AML during the corona pandemic (Lancet Haematology) and revising the International Working Group response criteria for higher risk MDS (Blood Journal). He is also founder and chair of the International Consortium for MDS (icMDS) which has championed important initiatives such as harmonizing the WHO and ICC classification systems (Lancet Haematology) and standardizing eligibility for MDS clinical trials (Blood Journal). Dr Zeidan also delivered many invited talks at National and International meetings including grand rounds in several prestigious institutions.

Dr. Zeidan’s work has been recognized by several prestigious awards including the Leukemia and Lymphoma Society Scholar in Clinical Research award, the National Cancer Institute Cancer Clinical Investigator Team Leadership award, the AAMDSIF/Evan’s Foundation-MDS Clinical Research Consortium Fellowship award, the Tito Bastianello Young Investigator Award, the ASCO Young Investigator Award, and multiple other achievement awards. Dr. Zeidan also serves on the editorial board and is a reviewer of several important hematology and oncology journals. He is an author on more than 360 peer-reviewed publications and book chapters and more than 250 scientific abstracts.